Compass Pathways Drug Approval·closes in 12mo

When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?

YES means Before October 2027

24h volume: 0; 2,346 lifetime
Open interest: 1,040; +0 over 30d
Spread: 7¢; 5.17 × 500 at the touch
24h range: –

Chance of YES

90%

A YES contract costs 90¢ and pays $1 if it happens.

10%

costs 17¢

YES bid / ask

83¢ / 90¢

NO bid / ask

10¢ / 17¢

What Galdor thinks

An independent read of this market

1Reads the rules literallySettlement source, close time, and the edge cases that flip an outcome.

2Checks the tape and the webOrder book, flow, price history, then targeted searches with sources.

3Gives a straight answerA probability with a band, and one of four calls: YES, NO, wait, or stay out.

Generated by an AI analyst from live exchange data and public web sources. Research and analytics, not investment advice. Markets can move after this was written.

Price history

YES price per candle with the bid/ask band, volume underneath. Times in UTC.

24h 7d 30d 90d

Order book

Resting orders, both sides shown as YES prices. Bars are size.

Order book unavailable.

How this market resolves

Verbatim from Kalshi. Read this before the price.

If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.

Settlement sources

Food and Drug Administration

opened: Mar 24 · 2:00 PM UTC
closes: Oct 1, 2027 · 3:59 AM UTC · may close early
settles by: Jan 1, 2028 · 3:00 PM UTC
ticker: KXFDAAPPROVALDATECMPS-360-27OCT01

Trade it on kalshi.com

This event

Outcomes in this event settle independently.

This is the only market in its event.

Prices are YES cost in cents and approximate the market’s implied probability. Data is read live from the Kalshi Trade API on every page load. galdor.xyz places no orders and holds no positions. Research and analytics, not investment advice.